Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Phio Pharmaceuticals (NASDAQ: PHIO) announced two podium presentations at the 11th Annual Immunotherapy of Cancer Conference in Munich, Germany on April 3, 2025. The presentations focus on their lead INTASYL siRNA product candidates:
1. PH-762: An INTASYL siRNA compound targeting PD-1, currently in clinical trials (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies. The therapy has shown promising preclinical efficacy and favorable tolerability.
2. PH-894: An INTASYL siRNA compound that selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, aimed at improving adoptive cell therapy.
The presentations will be delivered by Melissa Maxwell, Phio's Director of Research and Program Management, in Plenary Sessions 3 and 11 on April 3rd and 5th, 2025, respectively.
Phio Pharmaceuticals (NASDAQ: PHIO) ha annunciato due presentazioni in plenaria alla 11ª Conferenza Annuale sull'Immunoterapia del Cancro a Monaco di Baviera, Germania, il 3 aprile 2025. Le presentazioni si concentrano sui loro principali candidati di prodotto INTASYL siRNA:
1. PH-762: Un composto INTASYL siRNA che mira a PD-1, attualmente in fase di sperimentazione clinica (NCT 06014086) come terapia intratumorale neoadiuvante per le neoplasie cutanee. La terapia ha mostrato un'efficacia preclinica promettente e una tollerabilità favorevole.
2. PH-894: Un composto INTASYL siRNA che silenzia selettivamente BRD4, migliorando l'attivazione e la proliferazione delle cellule NK senza effetti off-target, con l'obiettivo di migliorare la terapia cellulare adottiva.
Le presentazioni saranno tenute da Melissa Maxwell, Direttore della Ricerca e della Gestione dei Programmi di Phio, nelle Sessioni Plenarie 3 e 11 rispettivamente il 3 e il 5 aprile 2025.
Phio Pharmaceuticals (NASDAQ: PHIO) anunció dos presentaciones en el podio en la 11ª Conferencia Anual sobre Inmunoterapia del Cáncer en Múnich, Alemania, el 3 de abril de 2025. Las presentaciones se centran en sus principales candidatos de productos INTASYL siRNA:
1. PH-762: Un compuesto INTASYL siRNA que apunta a PD-1, actualmente en ensayos clínicos (NCT 06014086) como terapia intratumoral neoadyuvante para malignidades cutáneas. La terapia ha mostrado una eficacia preclínica prometedora y una tolerabilidad favorable.
2. PH-894: Un compuesto INTASYL siRNA que silencia selectivamente BRD4, mejorando la activación y proliferación de células NK sin efectos fuera del objetivo, con el objetivo de mejorar la terapia celular adoptiva.
Las presentaciones serán realizadas por Melissa Maxwell, Directora de Investigación y Gestión de Programas de Phio, en las Sesiones Plenarias 3 y 11 el 3 y 5 de abril de 2025, respectivamente.
Phio Pharmaceuticals (NASDAQ: PHIO)는 2025년 4월 3일 독일 뮌헨에서 열리는 제11회 암 면역 요법 회의에서 두 개의 기조 발표를 발표했습니다. 발표는 그들의 주요 INTASYL siRNA 제품 후보에 초점을 맞추고 있습니다:
1. PH-762: PD-1을 타겟으로 하는 INTASYL siRNA 화합물로, 현재 피부 악성 종양에 대한 보조적 종양 내 치료로 임상 시험(NCT 06014086) 중입니다. 이 요법은 유망한 전임상 효능과 우수한 내약성을 보여주었습니다.
2. PH-894: BRD4를 선택적으로 침묵시키는 INTASYL siRNA 화합물로, 표적 이외의 효과 없이 NK 세포의 활성화 및 증식을 향상시켜 채택된 세포 치료를 개선하는 것을 목표로 합니다.
발표는 Phio의 연구 및 프로그램 관리 이사인 Melissa Maxwell이 2025년 4월 3일과 5일에 각각 기조 세션 3과 11에서 진행합니다.
Phio Pharmaceuticals (NASDAQ: PHIO) a annoncé deux présentations en podium lors de la 11e Conférence Annuelle sur l'Immunothérapie du Cancer à Munich, Allemagne, le 3 avril 2025. Les présentations portent sur leurs principaux candidats de produits INTASYL siRNA :
1. PH-762 : Un composé INTASYL siRNA ciblant PD-1, actuellement en essais cliniques (NCT 06014086) en tant que thérapie intratumorale néoadjuvante pour les malignités cutanées. La thérapie a montré une efficacité préclinique prometteuse et une tolérance favorable.
2. PH-894 : Un composé INTASYL siRNA qui silencieux sélectivement BRD4, améliorant l'activation et la prolifération des cellules NK sans effets hors cible, visant à améliorer la thérapie cellulaire adoptive.
Les présentations seront faites par Melissa Maxwell, Directrice de la Recherche et de la Gestion des Programmes chez Phio, lors des Sessions Plénières 3 et 11 les 3 et 5 avril 2025, respectivement.
Phio Pharmaceuticals (NASDAQ: PHIO) kündigte zwei Podiumspräsentationen auf der 11. jährlichen Konferenz zur Immuntherapie von Krebs in München, Deutschland, am 3. April 2025 an. Die Präsentationen konzentrieren sich auf ihre führenden INTASYL siRNA-Produktkandidaten:
1. PH-762: Eine INTASYL siRNA-Verbindung, die auf PD-1 abzielt und sich derzeit in klinischen Studien (NCT 06014086) als neoadjuvante intratumorale Therapie für kutane Malignome befindet. Die Therapie hat vielversprechende präklinische Wirksamkeit und günstige Verträglichkeit gezeigt.
2. PH-894: Eine INTASYL siRNA-Verbindung, die BRD4 selektiv zum Schweigen bringt und die Aktivierung und Proliferation von NK-Zellen ohne Off-Target-Effekte verbessert, mit dem Ziel, die adoptive Zelltherapie zu verbessern.
Die Präsentationen werden von Melissa Maxwell, der Direktorin für Forschung und Programmmanagement von Phio, in den Plenarsitzungen 3 und 11 am 3. und 5. April 2025 gehalten.
- Clinical trial progress with PH-762 showing promising preclinical efficacy
- PH-894 demonstrates successful NK cell activation without off-target effects
- Multiple podium presentation slots secured at major industry conference
- None.
- To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany
Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.
The ITOC conference provides a unique platform for the exchange of latest findings in immunotherapy of cancer to advance oncology drug development and delivery.
Melissa Maxwell, Phio's Director of Research and Program Management, was awarded two speaker presentations, as follows:
Plenary Session 3: New Targets and New Leads
Date and Time: April 3, 2025, 16.30 - 16.45 PM (CEST)
Title: Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy
PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating promising preclinical efficacy, favorable tolerability, and the potential to enhance immune responses while minimizing systemic side effects.
Plenary Session 11: What Cellular Therapies Need to Work
Date and Time: April 5, 2025, 12.15 - 12.30 PM (CEST)
Title: Silencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self- delivering RNAi approach
PH-894, an INTASYL siRNA compound, selectively silences BRD4, a key regulator of gene expression. PH-894 enhances NK cell activation and proliferation without off-target effects, presenting a promising strategy to improve adoptive cell therapy.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-Looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246881
FAQ
What are the two lead INTASYL product candidates presented by PHIO at the ITOC Conference?
What is the current development stage of PHIO's PH-762 treatment?
How does PHIO's PH-894 treatment work to improve cell therapy?
When and where will PHIO present their INTASYL product candidates in 2025?
